Wyeth Introduces Pristiq in US Retail Pharmacies
Posted on: Friday, 16 May 2008, 09:01 CDT
Wyeth Pharmaceuticals has announced that Pristiq, a new serotonin-norepinephrine reuptake inhibitor approved to treat adult patients with major depressive disorder, is now available in US retail pharmacies.
The recommended dose of Pristiq (desvenlafaxine) is 50mg once daily. The company has initiated full-scale selling and educational efforts regarding Pristiq for physicians. Dosage adjustment (50mg every other day) is necessary, however, in patients with severe renal impairment or end-stage renal disease.
Philip Ninan, vice president, Wyeth Medical Affairs, Neuroscience, said: "The recommended therapeutic dose of Pristiq is 50mg once daily. Titration is not required to reach the recommended therapeutic dose."
Source: Datamonitor
Related Articles
- Wyeth Withdraws Marketing Authorization Application of Vasomotor Drug
- Wyeth Reports Positive Pristiq Data
- Janssen Says FDA Approves New Lower Risperdal Dose
- FDA Approves New Dose for Wyeth Transplant Drug
- FDA Approves New Dosing Recommendations for RAPAMUNE in High Immunologic Risk Renal Transplant Patients
- Dosing Commenced in Phase IIa PBT2 Trial of Alzheimer's Patients
- Children May Need Two Doses of Chickenpox Vaccine
- Amgen's Aranesp Gets Widened Dosing Schedule
- Doctor: Celebrex Dose Key to Safe useAn Arthritis Expert Says There's Little Cause for Concern for Many.
- New Test Stirs Fears Over Safety of Celebrex A Local Expert Says Right Dose is Key
User Comments (0)
RSS Feeds